Isomorphic Labs lands $2.1B Series B to accelerate AI-driven drug discovery
Isomorphic Labs closed a $2.1 billion Series B, cementing its leadership in AI-driven drug discovery and prompting questions about how the funds will be deployed, pipeline progress, and the broader implications for biotech and AI investment.
